Company intelligence / Profile preview

Luoxin Pharmaceutical

Linyi, Shandong, China

Ownership: Private
Employees: ~5500
Development stage: Other

Overview

Luoxin Pharmaceutical is a top-100 Chinese pharma company with >300 marketed products and a robust pipeline. It has achieved commercial success with multiple generic and novel small molecule and biologic drugs. Recent clinical results include a Phase 3 trial for a potassium-competitive acid blocker (LXI-15028) meeting its primary endpoint in erosive esophagitis and ongoing co-development of a third-generation EGFR inhibitor for NSCLC with Yuhan[1][8].

Therapeutic areas: EndocrinologyInfectious DiseasesGastroenterologyPulmonologyCardiovascularOncologyNeurology
Modalities: Small moleculeBiologic
Industry: Pharma

Drug pipeline

1 asset

tigolaxant

Unknown

Partnerships

Marinomed Biotech AGAurobindo PharmaYuhanTeikoku Pharma USAJW Holdings

Beyond the preview

Go deeper on Luoxin Pharmaceutical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Luoxin Pharmaceutical.

Explore the full profile